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Aims Glycogen synthase kinase 3 (GSK-3) signalling is implicated in the growth of the heart during development and in
response to stress. However, its precise role remains unclear. We set out to characterize developmental growth
and response to chronic isoproterenol (ISO) stress in knockin (KI) mice lacking the critical N-terminal serines, 21
of GSK-3a and 9 of GSK-3b respectively, required for inactivation by upstream kinases.
Methods
and results
Between 5 and 15 weeks, KI mice grew more rapidly, but normalized heart weight and contractile performance were
similar to wild-type (WT) mice. Isolated hearts of both genotypes responded comparably to acute ISO infusion with
increases in heart rate and contractility. In WT mice, chronic subcutaneous ISO infusion over 14 days resulted in
cardiac hypertrophy, interstitial fibrosis, and impaired contractility, accompanied by foetal gene reactivation. These
effects were all significantly attenuated in KI mice. Indeed, ISO-treated KI hearts demonstrated reversible physiologi-
cal remodelling traits with increased stroke volume and a preserved contractile response to acute adrenergic stimu-
lation. Furthermore, simultaneous pharmacological inhibition of GSK-3 in KI mice treated with chronic subcutaneous
ISO recapitulated the adverse remodelling phenotype seen in WT hearts.
Conclusion Expression of inactivation-resistant GSK-3a/b does not affect eutrophic myocardial growth but protects against
pathological hypertrophy induced by chronic adrenergic stimulation, maintaining cardiac function and attenuating
interstitial fibrosis. Accordingly, strategies to prevent phosphorylation of Ser-21/9, and consequent inactivation of
GSK-3a/b, may enable a sustained cardiac response to chronic b-agonist stimulation while preventing pathological
remodelling.
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1. Introduction
Glycogen synthase kinase 3 (GSK-3) is a highly conserved serine/
threonine kinase implicated as a key signalling mediator in a range
of cardiovascular diseases, including ischaemic myocardial condition-
ing,1,2 myocardial hypertrophy,3,4 and progressive heart failure.5,6
Two isoforms, GSK-3a and GSK-3b, are ubiquitously expressed
with high sequence homology within their catalytic domains.7
Cardiac myocyte hypertrophy is a normal feature of both post-natal
eutrophic growth and adaptive physiological growth.8,9 Maladaptive
pathological hypertrophy, however, may result from myocardial
infarction, pressure overload or as a direct response to neurohor-
monal activation, often recapitulated experimentally using angiotensin
receptor, endothelin receptor or b-adrenoceptor agonists. At the
subcellular level, there is reactivation of foetal gene programmes,
differential protein expression, and altered intracellular calcium
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handling.10,11 Ultimately, these lead to irreversible interstitial fibrosis
and progressive contractile impairment.
GSK-3 has been identified in a variety of experimental models as an
important signalling mediator in all forms of myocardial hypertrophy
through direct inhibitory regulation of key downstream transcriptional
and translational effectors.12–14 Kinase activity is primarily controlled by
inactivation through N-terminal phosphorylation of serine-9 of GSK-3b
and serine-21 of GSK-3a. GSK-3b inactivation occurs in response to
pharmacological agonists (e.g. endothelin-1 and a- and b-adrenoceptor
agonists) and trans-aortic banding.4,15,16 Hypertrophy in response to
these interventions is significantly attenuated by overexpression of
inactivation-resistant GSK-3b (Ser-9-Ala).3,4 Likewise, co-expression of
this transgene with a mutant b-myosin heavy chain (b-MHC), to mimic
familial hypertrophic cardiomyopathy, reduces cardiac mass.17 Further-
more, temporally regulated GSK3-b overexpression suggests that reacti-
vation can regress established pressure-overload hypertrophy.18
Persistent prevention of GSK-3b inactivation within the heart raises
potential concerns, however. Overexpression of inactivation-resistant
or wild-type (WT) GSK-3b, for example, is associated with abnormal
developmental growth,3,11 while overexpression of kinase-dead
‘dominant-negative’ GSK-3b results in basal ventricular hypertrophy
but significantly reduces fibrosis, apoptosis, and cardiac dysfunction
in response to pressure overload.6 Further uncertainty is introduced
through manipulation of the equally abundant GSK-3a isoform, where
activation appears to reduce heart size but promote fibrosis, apopto-
sis, and heart failure after aortic banding.19
Although the heterogeneity in current data may, in part, reflect the
diversity in timing and isoform-specificity of GSK-3 targeting,
additional concerns have been highlighted in the common experimen-
tal use of transgene overexpression.20 More recently, a novel genetic
mouse model of endogenous GSK-3 allele targeting has been
described, in which the regulatory N-terminal serine residues are
selectively mutated to non-phosphorylatable alanine, rendering both
GSK-3 isoforms constitutively active.21 Prior characterization of this
line suggests normal developmental growth and response in adult
hearts to pressure overload.22 We set out to examine the response
in this mouse model to an alternative pro-hypertrophic stress, and
to further clarify any baseline and stress-induced cardiovascular
responses associated with constitutive GSK-3 activity.
2. Methods
Further Methods are available in the Supplementary material online. All
experiments performed conform with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996) and in accordance with United
Kingdom Home Office Guidance on the Operation of Animals (Scientific
Procedures) Act 1986, published by Her Majesty’s Stationary Office, London.
2.1 GSK-3a/b double-knockin mice
The targeting strategy and consequent effect on the PKB/Akt-GSK3-GS
signalling axis have been described before.21,23 Further experiments
were performed in this study using isolated murine hearts perfused
with isoproterenol (ISO) to confirm activation of PKB/Akt and character-
ize downstream signalling in WT and knockin (KI) mice.
2.2 GSK-3 signalling and acute haemodynamic
response to adrenergic stimulation
Adult male mice (25–30 g) were anaesthetized with intraperitoneal pen-
tobarbital (300 mg/kg) and heparin (150 U). Hearts were rapidly isolated
and perfused in Langendorff-mode, as described previously.23 A fluid-filled
balloon within the left ventricular (LV) cavity monitored contractile func-
tion and ventricular rate. After 30 min stabilization, the perfusate was then
switched every 10 min to a 10-fold greater concentration of ISO (Sigma,
I5627; Krebs–Henseleit buffer as a solvent, concentration range 10210–
1026 mol). Additional experiments were performed with 1028 mol ISO
(approximate log EC50) or control buffer only, perfused for 15 min after
stabilization and hearts snap-frozen in liquid nitrogen for protein analysis.
2.3 Chronic exposure to ISO and
(2′Z, 3′E)-6-bromoindirubin-3′-oxime
Subcutaneous 14-day osmotic pumps (Alzet, Durect; model 1002) con-
taining ISO (Sigma, I5627; 30 mg/kg/day) or vehicle (0.9% NaCl) were
inserted into adult mice (25–30 g males) under 2% isoflurane/oxygen
anaesthesia. To determine whether pharmacological inhibition of
GSK-3 activity would rescue myocardial sensitivity to ISO infusion
in KI mice, we used daily intraperitoneal delivery of (2′Z, 3′E)-
6-bromoindirubin-3′-oxime (300 mL of 50 nMol solution; Calbiochem,
361550), or BIO, previously shown to achieve sustained systemic kinase
inhibition in vivo.24 KI mice treated with BIO received daily intraperitoneal
injections for 14 days [300 mL of a 50 nMol BIO solution prepared in
DMSO:NaCl (0.9%), 1:10]. Confirmation of GSK-3 inhibition with this
protocol in our mice was determined through interrogation of the
GSK-3 endogenous substrate, glycogen synthase. Briefly, hearts from
WT and KI mice, subjected to intraperitoneal injection of BIO (300 mL
of 50 nMol BIO), were rapidly extracted at 4, 12, and 24 h and snap-frozen
in liquid nitrogen for immunoblotting and quantification of total and phos-
phorylated protein.
At 14 days, invasive LV pressure analysis and echocardiography were
performed. Hearts were excised for immunoblotting, histology, and
RT–PCR. Later experiments involved removal of pumps at Day 14, recov-
ery for an additional 14 days, and repeat echocardiography to assess
cardiac structure and function.
2.4 Morphometric analysis
Hearts arrested in diastole (300 mL of 15% KCl intracardiac) were
mounted on a Langendorff-rig surrounded by 10% paraformaldehyde
(PFA). LV chamber pressure was maintained at 10 mmHg and a further
10 mL of 10% PFA retrogradely perfused via the aorta. After 10 min,
the balloon was removed and hearts stored in 10% PFA at 48C for
24 h. Hearts were then placed in 2.5% glutaraldehyde for 1 min and set
in 5% agarose. Seven hundred-micrometre thick sections were
image-scanned for off-line analysis (Adobe Photoshop 7.0). Serial
measurements were taken at the level of the mid-papillary muscle.
2.5 Immunoblotting
Immunoblotting experiments set out to determine (i) the phosphorylation
status of GSK-3a/b, (ii) kinase activity through endogenous substrate
phosphorylation, and (iii) the integrity of the PKB/Akt-GSK-3 signalling
pathway in response to ISO stimulation. Full experimental materials are
included in the Supplementary material online.
2.6 Histology
Paraffin-mounted LV sections (8 mm) from the level of the mid-papillary
muscle were stained with picrosirius red (0.1% w/v), isolectin-B4
(Vector B-1205; 1:200), or wheat germ agglutinin–rhodamine (Vector
RL-1022; 1:50). Apoptosis was determined by terminal deoxynucleotidyl
transferase-mediated dUTP nick end-labelling (TUNEL) (Roche).
Cardiac fibrosis was calculated from picrosirius red-stained sections
viewed under circular polarized light, according to a modified Junqueira
method.25,26 Myocyte area (by planimetry), capillary density, and TUNEL-
positive nuclei were measured from images obtained by confocal
microscopy using digital analysis software (SigmaScan Pro 5.0).
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2.7 Real-time RT–PCR
Total RNA was purified from LV homogenate using an SV RNA extraction
kit (Promega, UK). Atrial natriuretic factor (ANF), a-skeletal actin (ASA),
and b-actin mRNA expression was analysed by real-time RT–PCR using
fluorescent SYBR Green technology on a Prism 7000 HT system
(Applied Biosystems, USA). Standard curves were constructed from
cDNA standards for ANF and ASA, and results normalized by expression
as a molar/molar ratio to b-actin. Details of primers are available in the
Supplementary material online.
2.8 Echocardiography
Serial echocardiography (Visualsonic Vevo 770TM, 30 MHz linear signal
transducer) was performed under isoflurane/oxygen anaesthesia before
pump implantation (Day 0), at Days 14 and 28. Averaged M-mode
measures from parasternal long-axis images were recorded. Interventricu-
lar septal and LV posterior wall (LVPW) dimensions were taken in diastole
and systole, in addition to LV internal dimensions (LVIDd and LVIDs,
respectively). Fractional shortening (FS) was calculated as (LVIDd 2
LVIDs/LVIDd) × 100 and ejection fraction as (LVIDd32 LVIDs3)/
LVIDd3 × 100.
Further interrogation of in vivo cardiac contractile performance by mag-
netic resonance imaging (MRI) and invasive haemodynamic measurements
appear in the Supplementary material online.
2.9 Statistical analyses
Data are presented as means+ SEM. Comparisons between groups were
assessed for significance by analysis of variance (ANOVA), repeated measures
ANOVA, or analysis of covariance (ANCOVA), as appropriate. When signifi-
cant differences were detected, individual mean values were compared by
Bonferroni’s post hoc test. P-values ,0.05 were considered significant.
3. Results
3.1 Characterization of GSK-3a/b
inactivation-resistant mice
GSK-3a/b KI mice were phenotypically comparable to WT animals
from the same colony. As previously reported, KI mice were
heavier over the 5–15 week age range evaluated (Figure 1A).21
However, normalized heart weight (HW) did not differ significantly
by genotype. Myocardial content of PKB/Akt, GSK-3, and glycogen
synthase protein was also comparable, consistent with existing data
(Figure 1B).21,23 Specifically, a- and b-isoforms were present in
approximately equal abundance and unchanged by targeting. In iso-
lated WT hearts, acute ISO exposure resulted in significant GSK-3b
Figure 1 Developmental growth and baseline characteristics of WT (GSK-3a/bSer-21/9) and KI (GSK-3a/bAla-21/9) mice. (A) Heart weight (HW),
body weight (BW), and tibia length (TL) measurements in a cohort of male mice between 5 and 15 weeks of age. n ¼ 25 (grey square, KI) and
n ¼ 20 (black circle, WT). (B) Representative western blots of isolated hearts perfused for 15 min with ISO (1028 mol) or control (Krebs–Henseleit
buffer). (C) GSK-3a/b phosphorylation profile in response to acute and chronic ISO exposure. Representative immunoblots are shown with quan-
titative analyses of repeat experiments expressed as the ratio of phosphorylated to total protein. Data expressed as mean+ SEM (n ¼ 4), *P, 0.05
vs. control. (D) Concentration–response relationship for isolated hearts perfused with ISO; dP/dtmax, contractile performance; HR, heart rate; LVDP,
left ventricular developed pressure. Black circle, WT; grey square, KI, n ¼ 6/group, NS between genotypes in all categories.
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(Ser-9), but not GSK-3a (Ser-21), phosphorylation (Figure 1B and C ).
Kinase activity in KI hearts was inferred through examination of down-
stream glycogen synthase, which is basally phosphorylated as a result
of constitutive GSK-3 activity and this was unchanged by acute ISO
treatment (Figure 1B). A similar GSK-3 phosphorylation profile was
demonstrated after 14 days treatment with chronic subcutaneous
ISO (Figure 1C).
Baseline haemodynamic measurements in isolated-perfused hearts
(Figure 1D) and in vivo from pressure-volume interrogation (data not
shown) were equivalent between genotypes. Similarly, dose–
response profiles to acute ISO stimulation did not differ (Figure 1D).
Specifically, peak, trough, and log EC50 measures of heart rate, LV
developed pressure (LVDP), and systolic contractile performance
(dP/dt) were all comparable between genotypes (see Supplementary
material online, Table S1).
3.2 Effects of chronic ISO exposure on
GSK-3a/b inactivation-resistant hearts
Chronic ISO treatment over 14 days caused a significant increase
in normalized HW in WT animals vs. within-genotype control
[HW/body weight (BW) 6.7+ 0.2 vs. 5.4+0.1, HW/tibia length
(TL) 9.1+0.3 vs. 7.2+ 0.1, respectively, n ≥ 10, P, 0.05]
(Figure 2A), consistent with increases in mean LV and septal wall thick-
ness measured from mounted sections at the level of the mid-papillary
muscle (1.9+0.04 vs. 1.3+0.09 and 1.5+0.07 vs. 1.1+0.06 mm,
respectively, n ¼ 6, P, 0.05) (Figure 2D and Table 1). Baseline HW/
BW and HW/TL ratios in age-matched KI mice tended to be higher
than WT, consistent with earlier phenotype characterization,
but did not differ significantly. KI hearts, however, were resistant to
ISO-driven hypertrophy with marked attenuation of the morphologi-
cal changes seen in WT counterparts, such as HW/BW and HW/TL
ratios (6.2+0.3 vs. 6.0+ 0.2 and 8.4+0.4 vs. 8.3+0.2, respectively,
n ≥ 10, NS) (Figure 2A), as well as mean LV and septal morphometry
in ISO and vehicle control (1.4+0.04 vs. 1.6+0.08 and 1.3+ 0.07
vs. 1.2+0.05 mm, respectively, n ¼ 6, NS) (Table 1). Invasive
measures of aortic pressure at 2 weeks treatment failed to detect
any significant differences between the genotypes or between ISO
and vehicle exposure (data not shown).
We then set out to determine whether pharmacological inhibition of
GSK-3 activity would rescue myocardial sensitivity to ISO treatment in
KI mice (Figure 2B). Initial examination of pGSK-3 and p-glycogen
synthase levels in hearts of both genotypes at 4 h after intraperitoneal
injection of BIO (300 mL of 50 nMol BIO) was able to confirm
reduction in glycogen synthase phosphorylation levels, independent
of GSK-3 phosphorylation status (Figure 2C). Sampling of glycogen
synthase and other endogenous substrates at 12 and 24 h, however,
gave inconclusive results, possibly due to cycling and heterogeneity of
upstream phosphorylating effectors and/or phosphatases.
We proceeded to daily intraperitoneal administration of BIO
(300 mL of 50 nMol) in KI mice treated with 14-day subcutaneous
ISO or vehicle; this latter group was considered more appropriate
than the WT controls in which GSK-3 activity is already inhibited
by ISO and a hypertrophic phenotype manifest. As demonstrated in
Figure 2A, BIO co-administration with ISO was able to restore hyper-
trophy in KI hearts compared with vehicle controls receiving BIO
alone (HW/BW: 7.3+ 0.2 vs. 5.4+ 0.2; HW/TL: 10.1+0.2 vs.
7.3+ 0.4, respectively, n ¼ 10, P, 0.05), with proportional changes
in mean LV wall thickness on cross-sectional morphology (mean LV
Figure 2 Response to chronic exposure to ISO or vehicle control and/or BIO. (A) Heart weight/body weight (HW/BW) and heart weight/tibia
length (HW/TL) in mice exposed to 14-day ISO, vehicle control (CON), and/or intraperitoneal BIO; n ≥ 10/group, *P, 0.05. (B) Protocol for
pharmacological GSK-3 inhibition; KI mice subjected to chronic 14-day exposure with ISO/CON additionally received daily intraperitoneal injections
of BIO (300 mL of 50 nmol). (C) Representative western blots from hearts snap-frozen at 4 h after intraperitoneal BIO injection. (D) Morphological
measurements of mean LV wall thickness recorded from 700 mm-thick sections at the mid-papillary level in hearts; n ¼ 6/group, *P, 0.05. (E) Repre-
sentative cross-sectional MR images of hearts at end-diastole at 14-day treatment. Images were acquired under isoflurane anaesthesia and are taken at
the level of the mid-papillary muscle.
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1.8+0.05 vs. 1.4+ 0.08 mm, respectively, n ¼ 6, P, 0.05) (Figure 2D
and Table 1). Importantly, however, GSK-3 inhibition alone in the
adult KI heart had no effect in the absence of adrenergic stimulation;
specifically, normalized HW measures and mean LV dimensions in this
group were comparable to KI hearts subjected to ISO, or control
without BIO, co-administration.
3.3 Fibrosis, apoptosis, and markers of
cellular hypertrophy with chronic ISO
We then examined whether the gross morphological changes in
response to stress were mirrored at the cellular level. Picrosirius
red staining was used to measure myocardial fibrosis, and confocal
immunofluorescence microscopy to measure myocyte cross-sectional
area, capillary density, and TUNEL-positive apoptotic nuclei. We
additionally interrogated mRNA transcripts for evidence of foetal
gene reactivation. WT hearts demonstrated a significant increase in
myocyte cross-sectional area (Figure 3B) in response to ISO vs.
control (628+ 78.8 vs. 395.8+ 33.6 mm2, n ¼ 5, P, 0.05, respect-
ively), accompanied by fibrosis, determined both by histology and
the up-regulation of genes encoding procollagen IaI, IIIaI, and fibro-
nectin (Figure 4A). Hypertrophied hearts also demonstrated increased
TUNEL-positive nuclei (Figure 3D). Additionally, ISO induced
up-regulation in genes encoding ASA and ANF (1.05+0.23 vs.
0.25+ 0.04% and 11.3+2.4 vs. 5.2+1.4%, respectively; n ¼ 8, P,
0.05 within each group) (Figure 4A), as well as an increase in capillary
density compared with control (9.4+ 1.1 vs. 6.0+0.7 mm22, n ¼ 5,
P, 0.05) (Figure 3C). All changes in these measures were significantly
attenuated in KI hearts in response to ISO, confirming resistance to
pathological hypertrophic changes.
3.4 Physiological assessment of chronic
ISO treatment and interval recovery
Serial echocardiography was performed before (baseline) and after
treatment with ISO/vehicle control (Day 14). A final scan was per-
formed 2 weeks after pump extraction (Day 28) to examine the poten-
tial for ‘reverse remodelling’ after removal of the stress stimulus. No
baseline differences in cardiac structure or function from non-invasive
assessment were evident between genotypes (Figure 5 and Table 2). In
response to ISO treatment, WT hearts demonstrated significant
increases in diastolic septal and LVPW thickness at Day 14 compared
with baseline (1.6+ 0.2 vs. 1.0+0.1 and 1.4+ 0.2 vs. 0.9+0.1 mm,
respectively, n ¼ 6, P, 0.05) (Figure 5 and Table 2). This was associated
with ventricular dilatation (4.1+0.5 vs. 3.4+0.2 and 3.2+ 0.3 vs.
1.5+0.3 mm, respectively, for LVIDd and LVIDs, n ¼ 6, P, 0.05)
and impairment of cardiac function (FS: 23+2 vs. 48+4%, n ¼ 6,
P, 0.05). At Day 28, there was apparent regression of hypertrophy
and a significant, but not fully reversible, reduction in internal LV dimen-
sions. Likewise, FS demonstrated some improvement but remained sig-
nificantly impaired (Table 2). Conversely, ISO-treated KI hearts
maintained contractile function at Days 14 and 28, but did demonstrate
reversible increases in internal LV dimensions in response to ISO
(LVIDd: 3.5+0.4, 4.4+0.6*, and 3.6+0.2 mm; LVIDs: 1.9+0.5,
2.7+0.6*, and 1.6+0.2 mm, respectively, for Days 0, 14, and 28;
n ¼ 6, *P, 0.05 vs. baseline), consistent with adaptive remodelling.
Similar findings were demonstrated in parallel, non-serial cardiac MRI
experiments (see Supplementary material online, Table S2). Specifically,
there was reversible dilatation of ISO-treated KI hearts, with attenu-
ation of contractile impairment compared with within-genotype
control. Indeed, indexed cardiac output and stroke volume significantly
increased in response to 2-week ISO treatment in this genotype
(713+ 61 vs. 458+ 38 mL/min g and 1.4+0.1 vs. 0.9+0.1 mL/g,
respectively, vs. KI CON, n ¼ 6, P, 0.05), consistent with a sustained
adrenergic response in these hearts. To explore this further, we
repeated experiments to interrogate interval ISO dose–response pro-
files in isolated-perfused hearts at the end of 14-day chronic adrenergic
stimulation (Day 14) and 14 days after subcutaneous pump removal
(Day 28) (Figure 6A). At Day 14, ISO-treated WT hearts demonstrated
a significant reduction in adrenergic sensitivity, with blunting of
dose–response profiles for LVDP and +dP/dt, compared with
within-genotype controls (Figure 6B). Conversely, there was no signifi-
cant difference in dose–response profiles for KI hearts compared with
baseline. At Day 28, adrenergic sensitivity appeared intact in isolated KI
hearts (Figure 6B), whereas there was a sustained and significant impair-
ment in treated WT hearts following cessation of ISO.
4. Discussion
Our results indicate that expression of inactivation-resistant GSK-3a/
b isoforms does not interfere with eutrophic myocardial growth or
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Table 1 Heart morphology data
GSK-3 WT GSK-3 KI GSK-3 KI 1 BIO
CON ISO CON ISO CON ISO
HW/BW (mg/g) 5.4+0.1 6.7+0.2* 6.0+0.2 6.2+0.3 5.4+0.2 7.3+0.2††
LV thickness (mm) 1.3+0.09 1.9+0.04* 1.6+0.08 1.4+0.04# 1.4+0.08 1.8+0.05††
Septal thickness (mm) 1.1+0.06 1.5+0.07* 1.2+0.05 1.3+0.07 1.1+0.05 1.3+0.07
LV septal thickness (mm) 0.2+0.03 0.4+0.06 0.4+0.06 0.2+0.05 0.3+0.09 0.5+0.09†
LV:septal ratio 1.2+0.03 1.3+0.05 1.4+0.04 1.0+0.15 1.3+0.08 1.4+0.08†
RV free wall thickness (mm) 0.5+0.06 0.6+0.03 0.6+0.03 0.5+0.03 0.5+0.04 0.6+0.05
After 14-day treatment with ISO or vehicle control, hearts were arrested in diastole (15% KCl), excised, and fixed in 10% paraformaldehyde with an intra-ventricular pressure of
10 mmHg. Mean left ventricular wall and septal thickness measurements were recorded from 700 mm-thick sections at the level of the mid-papillary muscle. n ¼ 6/group.
*P, 0.05 vs. CON (within genotype).
†P, 0.05 vs. KI ISO.
††P, 0.05 vs. KI ISO and KI CON + BIO.
#P, 0.05 vs. WT ISO.
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baseline cardiac function, but does avert the pathological hypertrophy
caused by chronic ISO stress. Specifically, the increases in myocardial
mass, interstitial fibrosis, and foetal gene expression in hearts of WT
mice are absent in those of KI mice. Indeed, KI hearts demonstrate a
paradoxical increase in indexed stroke volume and cardiac output at 2
weeks of treatment on MR imaging, a finding reversed on removal of
ISO stress. Furthermore, unlike WT animals, adrenergic sensitivity and
reserve are maintained in KI hearts treated with ISO, consistent with a
sustained permissive physiological response to adrenergic stimulation.
N-terminal phosphorylation and consequent inactivation of GSK-3
is considered a strategic point of convergence for myocardial hyper-
trophy under a variety of circumstances.27 Particular attention has
focused on GSK-3b as the predominant isoform mediating these
effects, with interventions that maintain GSK-3 in the active state
attenuating adverse remodelling.3,4 In particular, two independent lab-
oratories have both employed cardiac-specific expression of
haemagglutinin-tagged GSK-3bala9 under the control of an a-myosin
heavy chain (a-MHC) promoter.3,11 The resultant tagged protein
expression, however, vastly exceeds endogenous levels with corre-
sponding increases in kinase activity. Furthermore, the effects on
the expression of equally abundant GSK-3a are unknown. This is rel-
evant since overexpression of a-MHC-driven WT GSK-3a is associ-
ated with reduced cardiac growth, protection against trans-aortic
banding, but a paradoxical increase in apoptosis and fibrosis.19
However, it remains uncertain whether these changes truly reflect
the function of GSK-3a since there is an accompanying reciprocal
down-regulation of GSK-3b, highlighting the complexity of manipulat-
ing this signalling pathway by transgenic overexpression of individual
isoforms. Additionally, although baseline a-MHC promoter activity
is normally high in adult mice, suppression and isogene switching to
b-MHC are reported in experimental hypertrophy and cardiac
failure.10,28 Finally, transgene-driven overexpression in mouse hearts
is known to induce an unfolded protein response which can reverse
the expected phenotype.29
More recently, data have emerged in a novel mouse line expressing
inactivation-resistant GSK-3a- and b-isoforms, achieved through site
specific mutation of the N-terminal phosphorylation serine residues to
non-phosphorylatable alanine.21,22 Target protein expression is compar-
able between KI and WT animals. In response to pressure overload
induced by aortic constriction, KI mice demonstrated significant attenu-
ation in hypertrophy, interstitial fibrosis, and cardiac dysfunction, a phe-
notype largely attributable to b-isoform manipulation. Conversely,
GSK-3a KI mice demonstrated an exaggerated response to pressure
overload with significant hypertrophy and cardiac dysfunction. Addition-
ally, there was attenuation of myocyte proliferation during stress.22
We set out to interrogate the response in dual isoform KI animals
to an alternative hypertrophic stress and later to clarify the nature of
‘positive’ or ‘adaptive’ remodelling apparent from our early results.
We specifically addressed dual isoform manipulation given the high
structural homology between kinase domains and common
Figure 3 Myocyte cross-sectional area, capillary density, and TUNEL staining. Representative images (A) and quantitative analysis of (B) myocyte
cross-sectional area (red; wheat germ agglutinin–rhodamine), (C) capillary density (green; isolectin B4), and (D) TUNEL-positive nuclei; n ¼ 5/
group, *P, 0.05.
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Figure 4 Fibrosis and foetal gene reactivation. (A) Quantification of fibrosis and mRNA transcript abundance for procollagens IaI, IIIaI, and fibro-
nectin; n ¼ 5/group, *P, 0.05. Additional quantification of the foetal genes, ASA and ANF, was also preformed; n ¼ 8/group, *P, 0.05. All transcript
results are normalized to b-actin mRNA levels. (B) Representative examples of picrosirius red-stained LV sections (8 mm thick) viewed under circular
polarized light demonstrating the effect of ISO on cardiac fibrosis.
Figure 5 Echocardiographic measures of hearts subjected to ISO or vehicle control (CON). Serial studies were performed under isoflurane inhala-
tional anaesthesia at baseline (Day 0, black bar), after 2-week treatment (Day 14, grey bar), and after 2-week recovery (Day 28, white bar); n ¼ 6/
group, *P, 0.05 vs. within-group baseline measurements. (A) Representative long-axis parasternal echocardiographic images, IVS, interventricular
septum; LVID, left ventricular internal dimension; LVPW, left ventricular posterior wall. (B) FS [¼ (LVIDd2 LVIDs/LVIDd) × 100] and (C) Structural
heart measurements taken at the mid-papillary level; LVIDd/s represent end-diastole and end-systole LVID measurements, respectively.
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susceptibility to both endogenous upstream inactivating kinases and
exogenous pharmacological inhibitors,7,30 thereby providing a more
pragmatic strategy of interrogation and potential therapeutic target-
ing. Accordingly, while isoform-specific stress responses are likely,
it is important to establish the combined effect of kinase manipu-
lation in vivo. An example of this is seen with the protection
against stress-induced interstitial fibrosis in dual isoform KI hearts
in our study and in that previously reported using this model;22
this contrasts with isolated overexpression of non-inhibitable
GSK-3a-isoforms, in which pressure overload significantly increases
fibrosis.19 Nevertheless, it is noteworthy in our results that
interrogation of GSK-3 phosphorylation in response to acute ISO
treatment in WT hearts (Figure 1B) revealed significant increases in
N-terminal phosphorylation of the GSK-3b-isoform, compared with
GSK-3a and with baseline values. There were similar results at 14
days of ISO treatment (Figure 1C), suggesting dominance of
GSK-3b inhibition over GSK-3a during ISO stress signalling and,
thus, by implication the predominant mechanism of protection in
the double-KI mouse.
Consistent with early phenotype characterization,22 we observed a
small trend towards higher normalized HWs in male KI mice with
increasing age (Figure 1). However, hypertrophy protocols undertaken
in sex- and age-matched mice revealed no differences in baseline LV
cavity dimensions or contractile performance between 8 and 10
weeks of age (Tables 1 and 2; see Supplementary material online,
Table S2). Furthermore, extrapolation from two non-invasive modal-
ities in control animal groups in our protocols suggests that this equiv-
alence is maintained out to 12–14 weeks of age (Table 2; see
Supplementary material online, Table S2).
KI hearts were protected against pharmacological-induced stress
caused by subcutaneous administration of ISO at all levels of interrog-
ation. Specifically, there was attenuation of hypertrophy, contractile
dysfunction, interstitial fibrosis, apoptosis, and reactivation of pro-
hypertrophic foetal gene programmes, all of which were significantly
evident in WT hearts. Co-treatment with the pharmacological
GSK-3 inhibitor BIO recovered susceptibility to myocardial hypertro-
phy and contractile dysfunction, but only in the presence of agonist.
Interestingly, KI hearts did remodel in response to adrenergic stimu-
lation with significant LV chamber dilatation (Figure 5 and Table 2;
see Supplementary material online, Table S2). Since this was fully
reversible and not associated with the pathological cellular and sub-
cellular traits outlined previously, it is likely to reflect a ‘positive remo-
delling’ phenomenon, consistent with an adaptive physiological
response. In keeping with this, there was a sustained sensitivity to
acute adrenergic stimulation with ISO in isolated hearts (Figure 6B).
This was in direct comparison to WT hearts which were desensitized
after 2-week ISO, and in which the dose–response profile remained
blunted after 2-week recovery without treatment. It is tempting to
speculate that these reversible structural and functional changes in
KI hearts mirror the positive remodelling characteristics of physiologi-
cal hypertrophy and the athletic heart in humans.31,32 Although no
firm conclusions in this respect can be made from our experiments,
it appears that targeting both GSK-3 isoforms is nevertheless safe
over the experimental time frame examined.
The precise mechanisms involved in the protective effects of
catalytically active GSK-3 remain unclear, although it is likely to
involve regulation of gene and protein expression within the cardio-
myocyte. Several downstream transcription and translational factors
are directly regulated by GSK-3 activity.22 Furthermore, nuclear
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content of GSK-3 increases with pharmacological and mechanical
stress, although the extent and isoform preference of this remains
unclear.22,33,34 We undertook protein interrogation of related signal-
ling partners in ISO-treated hearts, including cyclin-D1, b-catenin,
p38, HDAC-2, and eif2B1, but were unable to identify any consistent
differences between genotypes (data not shown). It is also unclear
whether protection in this model of constitutive GSK-3 activity
would be afforded to other neurohormonal agonists in vivo, such
as phenylephrine, endothelin-1, or angiotensin II. Ultimately, it is
unlikely that a single kinase system integrates all pro-hypertrophic
signalling pathways, emphasizing the need for biologically relevant
models in the characterization of relevant cardiomyocyte
signalling and in determining the overall effects of single kinase
interventions.
Although the genetic strategy employed in this study avoids
the confounders of cardiac-specific transgene manipulation, other
potential limitations have been highlighted in this model.22 In particu-
lar, genetic manipulation of endogenous GSK-3 alleles may have
non-selective consequences over and above those of merely
preventing N-terminal phosphorylation and kinase inhibition.
Furthermore, ubiquitous expression beyond the cardiomyocyte may
exert important systemic or localized cardiovascular effects. It is
Figure 6 Chronic ISO treatment and recovery. (A) Experimental protocol: mice were treated for 2 weeks with subcutaneous ISO or vehicle and
recovered for 2 weeks after pump extraction. Serial echocardiography was performed at baseline, 14, and 28 days. Parallel experiments were under-
taken in chronic ISO-treated animals and hearts explanted for Langendorff-perfusion to test acute adrenergic sensitivity. (B) Dose–response profiles
to acute ISO exposure in isolated Langendorff-perfused hearts. Baseline response is compared with that at 2-week ISO treatment (left panel) and
2-week recovery (right panel), respectively. Absolute values are plotted. LVDP, left ventricular developed pressure, +dP/dt, systolic contractile per-
formance; HR, heart rate; n ¼ 6/group, *P, 0.05 vs. WT baseline, #P, 0.05 vs. KI treated/recovery groups.
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also acknowledged that the effects of pharmacological GSK-3 inhi-
bition with BIO may reflect off-target phenomena.
In conclusion, our findings support a strategic and permissive role for
GSK-3 signalling in maladaptive hypertrophic remodelling secondary to
chronic adrenergic stimulation. Generic strategies to maintain GSK-3a/
b active may prove a useful therapeutic target, but require further vali-
dation in other models of neurohormonal and pathophysiological stress.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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